SCHEMBL4969221

SCHEMBL4969221

COc1ccc(CNc2c(C)c(C)c3c(c2C)C(c2ccc(C)cc2)C(C)(C)O3)cc1OC

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 3/20 0.41
HIF1A Q16665 1/20 0.39
EPAS1 Q99814 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 5/20 0.38
GAA P10253 4/20 0.38
KDM4E B2RXH2 3/20 0.38
MAPT P10636 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
TLR4 O00206 1/20 0.37
HTR1A P08908 1/20 0.35
HTR7 P34969 1/20 0.35
HTR6 P50406 1/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2905880 0.99 POLB (0.42) POLBSMN1; SMN2LMNAHIF1AEPAS1
Hydrochloric Acid SCHEMBL2912613 0.90 ALDH1A1 (0.37) POLBSMN1; SMN2LMNAHIF1AEPAS1
SCHEMBL2911151 0.82 KMT2A (0.34) POLBSMN1; SMN2LMNAALDH1A1GAA
SCHEMBL4969907 0.82 HTT (0.40) SMN1; SMN2LMNAL3MBTL1ALDH1A1KDM4E
Hydrochloric Acid SCHEMBL2914481 0.80 LMNA (0.45) POLBSMN1; SMN2LMNAL3MBTL1ALDH1A1
SCHEMBL2913560 0.79 GAA (0.38) LMNAL3MBTL1ALDH1A1GAAMAPT
SCHEMBL27616609 0.79 CA12 (0.34) LMNAL3MBTL1ALDH1A1GAAKDM4E
SCHEMBL2909609 0.79 SMN1; SMN2 (0.32) POLBSMN1; SMN2LMNAKDM4EMAPT
SCHEMBL2912943 0.78 PKM (0.49) POLBSMN1; SMN2LMNAALDH1A1KDM4E
SCHEMBL2910924 0.78 KDM1A (0.40) LMNAHIF1AL3MBTL1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1408036-B1 PROCESS FOR PRODUCING BENZOFURAN DERIVATIVE TAKEDA PHARMACEUTICAL (JP) 2008-08-27 EP disclosed
US-7323577-B2 Process for producing benzofuran derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-29 US disclosed
US-20060142598-A1 Process for producing benzofuran derivative TAWADA HIROYUKI 2006-06-29 US disclosed
US-7034166-B2 Process for producing benzofuran derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-25 US disclosed
US-20040210066-A1 Process for producing benzofuran derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-10-21 US disclosed
EP-1408036-A1 PROCESS FOR PRODUCING BENZOFURAN DERIVATIVE Takeda Chemical Industries, Ltd. (JP) 2004-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040210066-A1 Process for producing benzofuran derivative IWS1, HAT1, BRD1 POLB 1656/4885SMN1; SMN2 3784/4885LMNA 2920/4885
US-20060142598-A1 Process for producing benzofuran derivative AHR, CBR3, HAT1 POLB 1921/4885SMN1; SMN2 3801/4885LMNA 2863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.